Last updated: February 12, 2026
What is the Drug NDC 24208-0720?
NDC 24208-0720 specifies Bacillus Calmette-Guérin (BCG) Immunotherapy, primarily used in bladder cancer treatment. It is marketed under the brand name TheraCys or similar variations. This biologic is a live attenuated strain of Mycobacterium bovis used intravesically.
Market Overview
Indications and Usage
- Primarily treats non-muscle invasive bladder cancer (NMIBC).
- Approved by FDA for carcinoma in situ (CIS) and high-grade tumors.
Market Size
- The global bladder cancer therapeutics market was valued at approximately $1.3 billion in 2022.
- BCG remains the standard of care for NMIBC, representing over 50% of the current treatment revenue in this segment.
- The U.S. Market accounts for around 60-70% of sales compared to international markets.
Key Competitors
- Merck's ImmuCYST (historical, mostly discontinued)
- Merck-licensed OncoTherapy products
- Emerging intravesical agents under clinical trials, such as immune checkpoint inhibitors and combination therapies.
Market Dynamics
Price Trends and Pricing Strategies
- The average wholesale price (AWP) for BCG products ranges broadly, historically between $1,200 to $1,500 per 81-mg dose.
- Commercial pricing varies depending on the manufacturer, payer negotiations, and regional regulations.
- In the U.S., BCG has faced supply shortages, impacting pricing, leading to a spike in costs during shortages.
Supply and Manufacturing
- Supply chain disruptions began around 2016 due to manufacturing issues at Sanofi and other suppliers.
- The FDA approved private manufacturing facilities to expand supply, slightly easing shortages by 2021-2022.
- The drug's biological nature limits generic competition, maintaining high prices.
Price Projections
Short-Term (1-2 Years)
- Anticipate stable pricing at $1,200–$1,500 per dose, with minor fluctuations driven by supply stability.
- Shortages could temporarily increase prices to $1,600–$2,000 per dose depending on regional distribution and availability.
Medium to Long-Term (3-5 Years)
- Introduction of biosimilars or new therapies may introduce price competition.
- Projected market entry of novel immunotherapies (e.g., immune checkpoint inhibitors) could reduce dependence on BCG, pressuring prices downward.
- Still, due to manufacturing complexities and low competition, the price may remain in the $1,200–$1,800 range.
Factors Influencing Price Trajectory
| Factor |
Impact |
| Regulatory approvals for biosimilars |
Potential downward pressure, but delayed |
| Supply chain stability |
Variability in prices, shortages increase costs |
| Advances in alternative therapies |
May diminish BCG demand, lowering prices |
| Regional reimbursement policies |
Influence actual patient prices and access |
| Patent and exclusivity periods |
Maintain pricing power during exclusivity |
Key Market Trends Impacting Future Price
- Supply Chain Enhancements: Improvements at manufacturing facilities reduce shortages, stabilize prices.
- Biologic Competition: Pending biosimilar approvals could reduce prices in 3-5 years.
- Therapeutic Developments: Clinical trials of checkpoint inhibitors and combination regimens may supplant BCG, impacting revenue and pricing.
- Regulatory Changes: US and international policies on biologic pricing and reimbursement influence profit margins.
Strategic Considerations
- Firms with proprietary manufacturing or supply agreements may sustain higher prices longer.
- Payers’ reluctance to reimburse high-cost biologics during shortages could influence pricing strategies.
- Clinical adoption depends on long-term efficacy data, affecting market share and pricing.
Key Takeaways
- NDC 24208-0720 (BCG) remains a high-demand biologic for bladder cancer, with prices around $1,200–$1,500 per dose.
- Supply issues caused temporary price rises, but ongoing manufacturing improvements are expected to stabilize costs.
- Future price reductions may occur with biosimilar entry and new therapies, but biologics' complexity suggests prices will stay relatively high.
- Market consolidation and regulatory policies significantly influence pricing dynamics.
- The drug's market remains positioned as the standard of care despite emerging competitors.
Frequently Asked Questions
1. What are the main factors affecting BCG price fluctuations?
Supply chain stability, manufacturing capacity, regional reimbursement policies, and the advent of biosimilars or new therapies influence prices.
2. How soon could biosimilars impact BCG pricing?
Potential biosimilars could enter the market within 3-5 years, likely causing downward pressure on prices.
3. Is there substantial international demand for this drug?
Yes, especially in Europe, Asia, and Latin America, where bladder cancer prevalence is comparable or higher.
4. What role do shortages play in pricing?
Shortages cause prices to spike temporarily, sometimes doubling or tripling the standard rate, until supply stabilizes.
5. Are there any regulatory actions that could significantly change the market?
Regulatory approval of biosimilars, supply measures, or policy shifts on biologic reimbursement could markedly influence prices.
Citations
[1] MarketWatch. "Bladder Cancer Therapeutics Market Size & Growth." 2022.
[2] U.S. Food and Drug Administration. "Bacillus Calmette-Guérin (BCG) for Intravesical Use." 2022.
[3] IQVIA. "Global Oncology Market Reports," 2022.
[4] ClinicalTrials.gov. "Emerging Immunotherapy Trials in Bladder Cancer." Accessed 2023.
[5] Statista. "Biologics Market Trends," 2022.
